Catalog No.: PC-49372Not For Human Use, Lab Use Only.
NYX-PCSK9i is an orally bioavailable small-molecule inhibitor of PCSK9, inhibits PCSK9-LDLR interaction with IC50 of 323 nM in in vitro biochemical binding assays.
NYX-PCSK9i is an orally bioavailable small-molecule inhibitor of PCSK9, inhibits PCSK9-LDLR interaction with IC50 of 323 nM in in vitro biochemical binding assays.
NYX-PCSK9i (30 and 50 mg/kg) demonstrates significant cholesterol-lowering properties in APOE*3-Leiden.CETP hyperlipidemic mice, significantly reduces plasma total cholesterol and elevates plasma total PCSK9 levels in a dose-dependent fashion.
NYX-PCSK9i enhances the efficacy of atorvastatin in lowering plasma total cholesterol levels in female APOE*3-Leiden.CETP mice.
NYX-PCSK9i modulates the hepatic transcriptional activity of specific genes involved in cholesterol metabolism (Pcsk9, Ldlr, Srebf2 and Mttp).
NYX-PCSK9i depletes hepatic cholesteryl ester levels and promotes faecal cholesterol elimination in female APOE*3-Leiden.CETP mice.
